Abstract Details

Title Remote Digital Self-Testing of Cognitive Impairment: Results of the re.cogni.ze Study on Feasibility and Acceptance with the NeotivCare App

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P9 - Poster Session 9 (11:45 AM-12:45 PM)

Poster/Presentation
Number 3-008

Objective To assess the feasibility, added value and satisfaction of remote digital self-assessment for mild cognitive impairment in primary and specialized routine care setting with a digital app certified as a medical device (neotivCare).

Background Cognitive tests provide key information for the diagnosis of mild cognitive impairment (MCI) and Alzheimer’s disease. In routine care, these tests are time-consuming and require trained personnel. Limited access to these assessments may delay timely diagnosis. We therefore developed a new digital remote self-assessment tool to address this challenge.

Design/Methods The multicentric study evaluated the usability of remote digital self-assessment neotivCare. neotivCare was installed on each patient’s own digital device. The application uses 3 different clinically and psychometrically validated tests of episodic memory. Each test is repeated once a week, four times in total, leading to an assessment period of 12 weeks. neotivCare calculates a composite score produces a summary of results.

Results

Of the 765 individuals with subjective cognitive impairment 574 patients (75%) followed the recommendation (mean age 67 - SD 10; 50.2% female) to use the app. 40% of participants with a composite score fell below the prevalidated cut-off for MCI while 60% performed within normal limits. Specialists reported a higher satisfaction with the app compared to standard paper-pencil tests (5.2 versus 4.4 on a 7 point Likert scale). 80% saw an added value in using the app and would use the app again. 71.5 % of the patients felt that the app was easy to use. 52% of the patients reported a reduction of previously experienced concerns and in 27% of all cases these concerns were unchanged.

Conclusions

Digital self-assessment in routine care is feasible and well accepted by health care providers and patients. neotivCare facilitates early diagnosis of cognitive impairment.

Authors/Disclosures
Gereon Nelles, MD, PhD, FAAN (Neurologische Praxis) PRESENTER	Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Industry. Dr. Nelles has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Industry. Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Industry. Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Industry. Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Industry. Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Industry. Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Industry. Dr. Nelles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Dr. Nelles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Memodio. Dr. Nelles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Industrial. Dr. Nelles has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Industry. Dr. Nelles has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Industry. Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Industry. Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Industry. Dr. Nelles has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for German Neurologists Professional Organization. Dr. Nelles has received publishing royalties from a publication relating to health care.
Emrah Duzel, MD	Prof. (DZNE) has received personal compensation for serving as an employee of neotiv. Prof. (DZNE) has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lilly. Prof. (DZNE) has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Prof. (DZNE) has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Prof. (DZNE) has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Prof. (DZNE) has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Prof. (DZNE) has stock in neotiv.
Claudia Bartels, PhD	Dr. Bartels has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly Deutschland GmbH. Dr. Bartels has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim Pharma GmbH & Co. KG. Dr. Bartels has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly Deutschland GmbH. Dr. Bartels has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai GmbH.
Dirk Czesnik, MD	Dr. Czesnik has nothing to disclose.
Thomas Duning, MD (Klinikum Bremen-Ost)	No disclosure on file
Andreas Lueschow	Andreas Lueschow has nothing to disclose.
Gerd Reifschneider, MD (NeuroCentrum Erbach)	Dr. Reifschneider has nothing to disclose.
Michael Schoettler, PhD	Dr. Schoettler has received personal compensation for serving as an employee of Roche Pharma AG.
Björn H. Schott, MD, PhD	The institution of Dr. Schott has received research support from DFG.
Martin Griebe, MD	Dr. Griebe has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche Pharma.

��ɫ��

��ɫ��